Incidence and risk factors for post-ERCP pancreatitis in chronic pancreatitis

被引:40
|
作者
Zhao, Zhen-Hua [1 ,2 ]
Hu, Liang-Hao [1 ]
Ren, Hong-Bo [3 ]
Zhao, An-Jing [1 ]
Qian, Yang-Yang [1 ]
Sun, Xiao-Tian [1 ]
Su, Song [1 ]
Zhu, Shu-Guang [1 ]
Yu, Jin [1 ]
Zou, Wen-Bin [1 ]
Guo, Xiao-Rong [1 ]
Wang, Lei [1 ]
Li, Zhao-Shen [1 ]
Liao, Zhuan [1 ]
机构
[1] Second Mil Med Univ, Natl Clin Res Ctr Digest Dis, Shanghai Inst Pancreat Dis, Dept Gastroenterol,Digest Endoscopy Ctr,Changhai, Shanghai, Peoples R China
[2] Jining 1 Peoples Hosp, Dept Gastroenterol, Jining, Shandong, Peoples R China
[3] Shandong Univ, Qilu Hosp, Dept Gastroenterol, Jinan, Shandong, Peoples R China
基金
中国国家自然科学基金;
关键词
M-ANNHEIM CLASSIFICATION; EUROPEAN-SOCIETY; COMPLICATIONS; SPHINCTEROTOMY; PROPHYLAXIS; MANAGEMENT;
D O I
10.1016/j.gie.2016.12.020
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background and Aims: Almost all studies on post-ERCP pancreatitis (PEP) have mainly involved patients with biliary diseases rather than chronic pancreatitis (CP), and the concept that CP seems to be a protective factor associated with PEP has not been studied in detail. The aim of this study was to determine the incidence of PEP in patients with CP at different clinical stages and to identify the predictive and protective factors of PEP in a large cohort. Methods: In this observational cohort study, medical records of patients with CP (CP group) and biliary diseases (BD group) in a tertiary hospital from January 2011 to May 2015 were examined. The difference in the incidence of PEP between CP group and BD group and the risk of PEP at different clinical stages of CP were calculated by the chi(2) test or the Fisher exact test. The predictive and protective factors for PEP were investigated by univariate and multivariate analysis. Results: In total, 2028 ERCP procedures were performed in 1301 patients with CP and 2000 procedures in 1655 patients with BD. The overall incidence of PEP in CP group (4.5%) was similar to that in the BD group (4.8%; P = .747). However, CP patients had significantly lower rates of moderate and severe attacks (0% vs 1.3%, P < .01). According to the M-ANNHEIM classification, the PEP incidences of CP at stages 0, I, II, III, and IV were 4.4%, 5.1%, 3.8%, 2.0%, and 2.0%, respectively. CP patients at stage Ia had the highest PEP incidence (8.0%) among all CP patients, significantly higher than that at stages Ib + Ic (3.9%) and II (3.8%). Female gender, history of acute pancreatitis, and prior PEP were independent risk factors of PEP, whereas extracorporeal shock wave lithotripsy was a protective factor. Conclusions: Compared with BD patients, CP patients had similar incidence of PEP overall but lower grades of severity. The incidence of PEP in CP patients decreased significantly with disease progression.
引用
收藏
页码:519 / U355
页数:7
相关论文
共 50 条
  • [41] Intramuscular diclofenac for the prevention of post-ERCP pancreatitis: a randomized trial
    Park, Se Woo
    Chung, Moon Jae
    Oh, Tak Geun
    Park, Jeong Youp
    Bang, Seungmin
    Park, Seung Woo
    Song, Si Young
    ENDOSCOPY, 2015, 47 (01) : 33 - 39
  • [42] Prophylactic somatostatin can reduce incidence of post-ERCP pancreatitis: multicenter randomized controlled trial
    Bai, Yu
    Ren, Xu
    Zhang, Xiao-Feng
    Lv, Nong-Hua
    Guo, Xue-Gang
    Wan, Xin-Jian
    Nie, Zhan-Guo
    Han, Shu-Tang
    Bie, Ping
    Tian, De-An
    Ji, Ming
    Li, Zhao-Shen
    ENDOSCOPY, 2015, 47 (05) : 415 - 420
  • [43] Incidence, Risk Factors, and Prevention Strategies for Post-ERCP Pancreatitis in Patients with Biliopancreatic Disorders and Acute Cholangitis: A Study from a Romanian Tertiary Hospital
    Cozma, Matei-Alexandru
    Angelescu, Cristina
    Haidar, Andrei
    Mateescu, Radu Bogdan
    Diaconu, Camelia Cristina
    BIOMEDICINES, 2025, 13 (03)
  • [44] A Preventive Effect of Unfractionated Heparin on Post-ERCP Pancreatitis is Suggested by Positive Effects on Laboratory Markers
    Ung, Kjell-Arne
    Rydberg, Lars
    Modin, Stefan
    Kyleback, Anders
    Modin, Marina
    HEPATO-GASTROENTEROLOGY, 2011, 58 (105) : 168 - 173
  • [45] Can rectal NSAIDs prevent post-ERCP pancreatitis?
    Testoni, Pier Alberto
    NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY, 2012, 9 (08) : 429 - 430
  • [46] Post-ERCP pancreatitis: review of current preventive strategies
    Feurer, Matthew E.
    Adler, Douglas G.
    CURRENT OPINION IN GASTROENTEROLOGY, 2012, 28 (03) : 280 - 286
  • [47] Rectal diclofenac does not prevent post-ERCP pancreatitis in consecutive high-risk and low-risk patients
    Lourdes del-Olmo-Martinez, M.
    Velayos-Jimenez, Benito
    Almaraz-Gomez, Ana
    REVISTA ESPANOLA DE ENFERMEDADES DIGESTIVAS, 2018, 110 (08) : 505 - 509
  • [48] The effect of nafamostat mesilate infusion after ERCP for post-ERCP pancreatitis
    Kim, Joo Seong
    Lee, Sang Hyub
    Park, Namyoung
    Huh, Gunn
    Chun, Jung Won
    Choi, Jin Ho
    Cho, In Rae
    Paik, Woo Hyun
    Ryu, Ji Kon
    Kim, Yong-Tae
    BMC GASTROENTEROLOGY, 2022, 22 (01)
  • [49] Risk factors of post-ERCP pancreatitis in high-risk patients despite prevention with prophylactic pancreatic stents
    Dubravcsik, Zsolt
    Hritz, Istvan
    Szepes, Attila
    Madacsy, Laszlo
    SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2020, 55 (01) : 95 - 99
  • [50] Obesity with abundant subcutaneous adipose tissue increases the risk of post-ERCP pancreatitis
    Fujisawa, Toshio
    Kagawa, Koichi
    Hisatomi, Kantaro
    Kubota, Kensuke
    Sato, Hajime
    Nakajima, Atsushi
    Matsuhashi, Nobuyuki
    JOURNAL OF GASTROENTEROLOGY, 2016, 51 (09) : 931 - 938